News
-
-
PRESS RELEASE
Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
Promatix Biosciences presents positive preclinical data at the 16th World ADC London Summit on PBS293-MMAE, a novel bispecific ADC for colorectal cancer, demonstrating enhanced tumour selectivity and efficacy